Kidney Disease Amplifies Cardiovascular Risk in Device-Detected Atrial Fibrillation: NOAH-AFNET 6 Analysis

How Does Kidney Disease Affect Outcomes in Device-Detected Atrial Fibrillation?

The NOAH-AFNET 6 trial, a landmark randomized controlled trial investigating anticoagulation therapy in patients with atrial high-rate episodes (AHRE) detected by pacemakers or defibrillators, has yielded important new findings about the intersection of kidney disease and cardiovascular risk. A prespecified subgroup analysis examined how baseline kidney function — measured by estimated glomerular filtration rate (eGFR) — influenced cardiovascular outcomes among trial participants.

Chronic kidney disease (CKD) and atrial fibrillation frequently coexist, with each condition known to worsen the prognosis of the other. According to the European Society of Cardiology, patients with both conditions face a compounded risk of stroke and systemic thromboembolism. The new NOAH-AFNET 6 analysis provides trial-level evidence quantifying this interaction specifically in the growing population of patients whose arrhythmia is identified through implanted device monitoring rather than conventional ECG.

What Are the Clinical Implications for Treatment Decisions?

The original NOAH-AFNET 6 trial, published in the New England Journal of Medicine, compared edoxaban — a direct oral anticoagulant — against placebo or aspirin in patients with AHRE but without clinically diagnosed atrial fibrillation on ECG. The trial's primary findings showed that edoxaban did not significantly reduce a composite of cardiovascular death, stroke, or systemic embolism compared to placebo in this population. However, this new kidney function analysis adds an important layer of nuance to clinical decision-making.

Patients with reduced eGFR experienced a markedly higher rate of the composite cardiovascular endpoint regardless of treatment assignment. This suggests that kidney function serves as a powerful risk modifier in this patient population. Professional societies including the European Heart Rhythm Association have already recommended kidney function assessment in AF management, but these results may strengthen the case for incorporating renal status into risk stratification algorithms specifically designed for subclinical or device-detected arrhythmias. The findings also raise questions about whether patients with both AHRE and CKD might represent a subgroup that benefits from anticoagulation, warranting further dedicated trials.

Why Is Device-Detected Atrial Fibrillation Different From Standard AF?

Atrial high-rate episodes detected by cardiac implanted electronic devices represent a distinct clinical entity from conventional atrial fibrillation diagnosed on surface ECG. These episodes are often brief, lasting minutes to hours, and patients are frequently asymptomatic. The thromboembolic risk associated with AHRE remains a subject of active research and debate, as it appears to be lower than that of clinically overt AF but still elevated above baseline.

The growing use of pacemakers, implantable cardioverter-defibrillators, and cardiac monitors means that AHRE is being detected with increasing frequency. According to estimates from the European Society of Cardiology, device-detected atrial arrhythmias are found in approximately 30 to 70 percent of patients with implanted devices, depending on the population studied and detection thresholds used. The NOAH-AFNET 6 kidney analysis underscores that not all AHRE patients carry the same risk — those with coexisting kidney disease may warrant closer surveillance and potentially different therapeutic approaches than those with preserved renal function.